NASDAQ:PDEX Pro-Dex (PDEX) Stock Price, News & Analysis $33.87 +0.76 (+2.30%) Closing price 02/25/2025 04:00 PM EasternExtended Trading$33.72 -0.14 (-0.43%) As of 02/25/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Pro-Dex Stock (NASDAQ:PDEX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Pro-Dex alerts:Sign Up Key Stats Today's Range$31.81▼$33.8850-Day Range$32.00▼$57.7852-Week Range$16.39▼$59.60Volume14,451 shsAverage Volume29,115 shsMarket Capitalization$110.45 millionP/E Ratio16.85Dividend YieldN/APrice Target$52.00Consensus RatingBuy Company OverviewPro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.Read More… Pro-Dex Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScorePDEX MarketRank™: Pro-Dex scored higher than 75% of companies evaluated by MarketBeat, and ranked 255th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingPro-Dex has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoveragePro-Dex has received no research coverage in the past 90 days.Read more about Pro-Dex's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth3.00% Earnings GrowthEarnings for Pro-Dex are expected to grow by 3.00% in the coming year, from $2.00 to $2.06 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pro-Dex is 16.85, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 23.68.Price to Earnings Ratio vs. SectorThe P/E ratio of Pro-Dex is 16.85, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.62.Price to Book Value per Share RatioPro-Dex has a P/B Ratio of 3.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Pro-Dex's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.86% of the float of Pro-Dex has been sold short.Short Interest Ratio / Days to CoverPro-Dex has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pro-Dex has recently decreased by 3.24%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPro-Dex does not currently pay a dividend.Dividend GrowthPro-Dex does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.86% of the float of Pro-Dex has been sold short.Short Interest Ratio / Days to CoverPro-Dex has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pro-Dex has recently decreased by 3.24%, indicating that investor sentiment is improving. News and Social MediaN/ANews SentimentN/A Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Pro-Dex insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,239,312.00 in company stock.Percentage Held by Insiders47.50% of the stock of Pro-Dex is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 15.28% of the stock of Pro-Dex is held by institutions.Read more about Pro-Dex's insider trading history. Receive PDEX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pro-Dex and its competitors with MarketBeat's FREE daily newsletter. Email Address PDEX Stock News HeadlinesInsider Selling: Pro-Dex, Inc. (NASDAQ:PDEX) Director Sells 1,100 Shares of StockFebruary 4, 2025 | insidertrades.comPro Dex director Cabillot sells shares worth $560,229January 28, 2025 | msn.comThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…February 26, 2025 | Crypto 101 Media (Ad)Pro dex director Raymond Cabillot sells shares worth $94,577January 24, 2025 | msn.comPro Dex Inc director Raymond Cabillot sells $409,925 in stockJanuary 22, 2025 | msn.comPro Dex director Raymond Cabillot sells shares worth $371,988January 17, 2025 | msn.comReturns On Capital At Pro-Dex (NASDAQ:PDEX) Have StalledJanuary 13, 2025 | uk.finance.yahoo.comPro-Dex (NASDAQ:PDEX) shareholders have earned a 22% CAGR over the last five yearsDecember 24, 2024 | uk.finance.yahoo.comSee More Headlines PDEX Stock Analysis - Frequently Asked Questions How have PDEX shares performed this year? Pro-Dex's stock was trading at $46.75 at the beginning of the year. Since then, PDEX shares have decreased by 27.6% and is now trading at $33.87. View the best growth stocks for 2025 here. How were Pro-Dex's earnings last quarter? Pro-Dex, Inc. (NASDAQ:PDEX) announced its quarterly earnings data on Thursday, January, 30th. The medical instruments supplier reported $0.61 EPS for the quarter, topping analysts' consensus estimates of $0.38 by $0.23. Pro-Dex had a net margin of 11.06% and a trailing twelve-month return on equity of 21.68%. Who are Pro-Dex's major shareholders? Pro-Dex's top institutional shareholders include Dimensional Fund Advisors LP (1.79%), Northern Trust Corp (1.10%), Geode Capital Management LLC (0.83%) and EAM Investors LLC (0.69%). Insiders that own company stock include Alisha Charlton and Angelita Rebamontan Domingo. View institutional ownership trends. How do I buy shares of Pro-Dex? Shares of PDEX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pro-Dex own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pro-Dex investors own include NVIDIA (NVDA), Broadcom (AVGO), Novo Nordisk A/S (NVO), Adobe (ADBE), ServiceNow (NOW), Arista Networks (ANET) and Jabil (JBL). Company Calendar Last Earnings1/30/2025Today2/25/2025Next Earnings (Estimated)5/01/2025Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:PDEX CUSIPN/A CIK788920 Webwww.pro-dex.com Phone(949) 769-3200Fax949-769-3281Employees140Year FoundedN/APrice Target and Rating Average Stock Price Target$52.00 High Stock Price Target$52.00 Low Stock Price Target$52.00 Potential Upside/Downside+57.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$2.01 Trailing P/E Ratio16.42 Forward P/E Ratio16.50 P/E GrowthN/ANet Income$2.13 million Net Margins11.06% Pretax Margin14.34% Return on Equity21.68% Return on Assets12.40% Debt Debt-to-Equity Ratio0.33 Current Ratio2.58 Quick Ratio1.44 Sales & Book Value Annual Sales$61.00 million Price / Sales1.76 Cash Flow$0.95 per share Price / Cash Flow34.81 Book Value$9.76 per share Price / Book3.38Miscellaneous Outstanding Shares3,261,000Free Float1,712,000Market Cap$107.61 million OptionableNot Optionable Beta0.53 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free Report This page (NASDAQ:PDEX) was last updated on 2/26/2025 by MarketBeat.com Staff From Our PartnersTrump's Nvidia Nightmare?Something strange is happening in Silicon Valley... Microsoft, Google, and Amazon are making unusual prepar...Banyan Hill Publishing | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | Sponsored(1) Elon Musk’s Final Project REVEALEDThe world’s richest man has an ace up his sleeve. You see, while everyone is talking about Elon Musk’s plan...Paradigm Press | SponsoredMust-See: Trump’s Shocking AI AnnouncementIf you have any investments in AI stocks or are interested in AI… Please take a moment to review the detail...Brownstone Research | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredIgnore Fox Business’s “man who calls it all” at your perilThis is the biggest AI investment story you’ve never been told… and people who invest before March 19 could st...The Oxford Club | SponsoredDiscover the Key to a Resilient Investment PortfolioThese 3 Stocks Should Do Well Even in a Recession If you’re looking for stocks that offer significant upsid...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pro-Dex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pro-Dex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.